If a company is not complying with cGMP
regulations, any drug it makes is considered “adulterated” under the law. This
kind of adulteration means that the drug was not manufactured under conditions
that comply with cGMP. It does not mean that there is necessarily something
wrong with the drug.
For consumers currently taking medicines from
a company that was not following cGMPs, FDA usually advises these consumers not
to interrupt their drug therapy, which could have serious implications for
their health. Consumers should seek advice from their health care professionals
before stopping or changing medications. Regulatory actions against companies
with poor cGMPs are taken as a preventive measure because the manufacturing
processes do not meet FDA’s regulatory standards. By focusing on the procedures
and processes used to make these drugs, FDA is working to ensure that drugs
meet their quality standards and are safe and effective. The impact of cGMP
violations depends on the nature of those violations and on the specific drugs
involved. A drug manufactured in violation of cGMP may still meet its labeled
specifications, and the risk that the drug is unsafe or ineffective could be
minimal. Thus, FDA’s advice will be specific to the circumstances, and health
care professionals are best able to balance risks and benefits and make the
right decision for their patients.
No comments:
Post a Comment